These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30429384)

  • 1. Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India.
    Veeraraghavan B; Pragasam AK; Bakthavatchalam YD; Anandan S; Ramasubramanian V; Swaminathan S; Gopalakrishnan R; Soman R; Abraham OC; Ohri VC; Walia K
    Indian J Med Microbiol; 2018; 36(3):334-343. PubMed ID: 30429384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro assessment of newer colistin-sparing antimicrobial agents for clinical isolates of carbapenem-resistant organisms.
    Saxena S; Aggarwal P; Mitra S; Singh S; Kaim M; Sharma A
    J Infect Chemother; 2024 Dec; 30(12):1252-1258. PubMed ID: 38839032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
    Kaye KS; Pogue JM
    Pharmacotherapy; 2015 Oct; 35(10):949-62. PubMed ID: 26497481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of newer β lactams/ β lactamase inhibitors for treatment of multidrug resistant gram negative infections in burn patients.
    Gupta K; Dash S
    Burns; 2019 Nov; 45(7):1725-1726. PubMed ID: 31445712
    [No Abstract]   [Full Text] [Related]  

  • 9. Preserving the Dwindling β-lactams-Based Empiric Therapy Options for Gram-Negative Infections in Challenging Resistance Scenario: Lessons Learned and Way Forward.
    Palwe S; Khobragade K; Kharat AS
    Microb Drug Resist; 2020 Jun; 26(6):637-651. PubMed ID: 31851576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.
    MacVane SH
    J Intensive Care Med; 2017 Jan; 32(1):25-37. PubMed ID: 26772199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms.
    Koenig C; Kuti JL
    Pharmacotherapy; 2024 Aug; 44(8):658-674. PubMed ID: 38949413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of new β-lactamase inhibitors in gram-negative infections.
    Vena A; Castaldo N; Bassetti M
    Curr Opin Infect Dis; 2019 Dec; 32(6):638-646. PubMed ID: 31577557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].
    Probst-Kepper M; Geginat G
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations?
    Gatti M; Virgili G; Viale P; Pea F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107177. PubMed ID: 38643849
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular epidemiology of beta-lactamase producing nosocomial Gram-negative pathogens from North and South Indian hospitals.
    Khurana S; Mathur P; Kapil A; Valsan C; Behera B
    J Med Microbiol; 2017 Jul; 66(7):999-1004. PubMed ID: 28671522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.
    Bush K; Fisher JF
    Annu Rev Microbiol; 2011; 65():455-78. PubMed ID: 21740228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the development of β-lactamase inhibitors.
    Jalde SS; Choi HK
    J Microbiol; 2020 Aug; 58(8):633-647. PubMed ID: 32720096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Delhi metallo-β-lactamase (NDM-1): an update.
    Shakil S; Azhar EI; Tabrez S; Kamal MA; Jabir NR; Abuzenadah AM; Damanhouri GA; Alam Q
    J Chemother; 2011 Oct; 23(5):263-5. PubMed ID: 22005056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.